ArticleCureus2025
Temporal Trends in Mortality Related to Hyperthyroidism and Heart Failure in the United States.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHyperthyroidism is one of the most frequently diagnosed disorders in the United States (US), and its association with heart failure (HF) remains underexplored. Understanding this relationship is critical for identifying high-risk populations and guiding preventive efforts.
aimsThis study aimed to analyze temporal and demographic trends in mortality where hyperthyroidism was the underlying cause and HF a contributing cause, using national data from 1999 to 2020. METHODOLOGY: A retrospective observational study was conducted using the Centers for Disease Control and Prevention (CDC) Multiple Causes of Death (MCD) database to assess mortality trends in individuals aged ≥25 years in the US from 1999 to 2020. The study included deaths in which hyperthyroidism (ICD-E05) was listed as an underlying cause and HF (ICD-i50) as a contributing cause. Data were analyzed by gender, race, geographic area, and place of death. Age-adjusted mortality rates (AAMRs) and annual percentage changes (APCs) were calculated.
resultsA total of 1,189 deaths were documented. The AAMR initially increased (25.95% APC from 1999 to 2001), followed by a decline from 2001 to 2011 (-5.04% APC); however, it increased from 2011 to 2020 (1.83% APC). The highest mortality was observed in females (70%), White individuals (73.93%), and those living in metropolitan regions (75.4%). Temporal trends showed an increasing AAMR in females (APC: +3.74% after 2013) and White individuals (APC: 8.16% from 2017 to 2020), indicating evolving disparities.
conclusionsMortality trends in hyperthyroidism with HF have shifted, with increasing disparities in gender and race. These findings emphasize the need for targeted prevention strategies and improved healthcare access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.